Weber, Manuel

Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study

Gafita, A., Calais, J., Grogan, T. R., Hadaschik, B., Wang, H., Weber, M., Sandhu, S., Kratochwil, C., Esfandiari, R., Tauber, R., et al. (2021) · The Lancet Oncology

Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and Research

Cited by 271

Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer

Fendler, W. P., Weber, M., Iravani, A., Hofman, M. S., Calais, J., Czernin, J., Ilhan, H., Saad, F., Small, E. J., Smith, M. R., et al. (2019) · Clinical Cancer Research

Prostate Cancer Diagnosis and TreatmentProstate Cancer Treatment and Research

Cited by 266

PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis

Seifert, R., Kessel, K., Schlack, K., Weber, M., Herrmann, K., Spanke, M., Fendler, W. P., Hadaschik, B., Kleesiek, J., Schäfers, M., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging

Radiopharmaceutical Chemistry and ApplicationsMedical Imaging Techniques and Applications

Cited by 160